ClinicalTrials.gov
ClinicalTrials.gov Menu

The Effects of the Endocrine System on Endometrial Cancer (Ghrelin)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01075386
Recruitment Status : Active, not recruiting
First Posted : February 25, 2010
Last Update Posted : April 5, 2018
Sponsor:
Collaborators:
Greenslopes Private Hospital
The University of Queensland
Sullivan and Nicolaides Pathology
Information provided by (Responsible Party):
Queensland Centre for Gynaecological Cancer

Brief Summary:
Endometrial cancer usually begins in the endometrium, which is the tissue lining of the uterus. Endometrial cancer is the most commonly diagnosed gynaecological malignancy in Australia. It affects 1 in 80 Australian women and there are about 1400 new cases and 260 deaths from the disease every year. Most affected women are aged between 50 and 70 years. The purpose of this study is to investigate the possible role of the endocrine system in the regulation of human endometrial cancer. By looking at the laboratory results of people with endometrial cancer and also those without endometrial cancer we hope to gain a better understanding of how endometrial cancer develops and progresses. This may lead to the development of new, effective therapies for endometrial cancer.

Condition or disease
Endometrial Cancer

Study Type : Observational
Estimated Enrollment : 80 participants
Observational Model: Case-Control
Time Perspective: Prospective
Official Title: Expression and Function of Ghrelin and Its Receptor, Growth Hormone Secretagogue Receptor TWEAK Protein and Its Receptor Fn14 in Human Endometrial Cancer
Actual Study Start Date : October 2009
Actual Primary Completion Date : August 2011
Estimated Study Completion Date : December 2019

Group/Cohort
Grade 2
Patients with Endometrial cancer of Grade 1 differentiation
Benign
Patients without endometrial cancer
Grade 1
Patients with Endometrial cancer of Grade 2 differentiation
Grade 3
Patients with Endometrial cancer of Grade 3 differentiation



Biospecimen Retention:   Samples Without DNA
Endometrial tissue


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with endometrial cancer and patients who are having a hysterectomy for non-cancerous conditions such as fibroids, chronic pelvis pain or abnormal uterine bleeding are eligible for the study
Criteria

Inclusion Criteria:

  • women aged 18 years or older
  • having a hysterectomy for the treatment of endometrial cancer, fibroids, chronic pelvic pain or abnormal uterine bleeding
  • have provided informed consent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01075386


Locations
Australia, Queensland
Greenslopes Private Hospital
Greenslopes, Queensland, Australia, 4120
Sponsors and Collaborators
Queensland Centre for Gynaecological Cancer
Greenslopes Private Hospital
The University of Queensland
Sullivan and Nicolaides Pathology
Investigators
Study Chair: Chen Chen, MD PhD The University of Queensland

Responsible Party: Queensland Centre for Gynaecological Cancer
ClinicalTrials.gov Identifier: NCT01075386     History of Changes
Other Study ID Numbers: Endo01
First Posted: February 25, 2010    Key Record Dates
Last Update Posted: April 5, 2018
Last Verified: April 2018

Keywords provided by Queensland Centre for Gynaecological Cancer:
Hysterectomy
Endometrial cancer
Benign
Endocrine system
Tissue collection

Additional relevant MeSH terms:
Endometrial Neoplasms
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Uterine Diseases
Genital Diseases, Female